Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus.

Vilsbøll T, Brock B, Perrild H, Levin K, Lervang HH, Kølendorf K, Krarup T, Schmitz O, Zdravkovic M, Le-Thi T, Madsbad S

Diabetic medicine : a journal of the British Diabetic Association14 Jan 2008Cited by 167 (Europe PMC)

PMID18201212DOI10.1111/j.1464-5491.2007.02333.xPepBankPUB-18201212

Publisher page PubMedAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, liraglutide had no significant treatment effect on glucose effectiveness.
In plain wordsIn people with type 2 diabetes, liraglutide did not significantly change glucose effectiveness compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeGlucose effectiveness
Study
n = 39
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.65, 1.25 or 1.9 mg/day · 14 weeksAs given in this study (human).
Source sentences
Summary
There was no significant treatment effect on glucose effectiveness or insulin sensitivity.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the effect of liraglutide, a once-daily human glucagon-like peptide-1 analogue on pancreatic B-cell function. methods: Patients with Type 2 diabetes (n = 39) were randomized to treatment with 0.65, 1.25 or 1.9 mg/day liraglutide or placebo for 14 weeks.
Report a problemFND-1820121207
02HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, liraglutide had no significant treatment effect on insulin sensitivity.
In plain wordsIn people with type 2 diabetes, liraglutide did not significantly change insulin sensitivity compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeInsulin sensitivity
Study
n = 39
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.65, 1.25 or 1.9 mg/day · 14 weeksAs given in this study (human).
Source sentences
Summary
There was no significant treatment effect on glucose effectiveness or insulin sensitivity.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the effect of liraglutide, a once-daily human glucagon-like peptide-1 analogue on pancreatic B-cell function. methods: Patients with Type 2 diabetes (n = 39) were randomized to treatment with 0.65, 1.25 or 1.9 mg/day liraglutide or placebo for 14 weeks.
Report a problemFND-1820121208
03HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, liraglutide 1.25 mg/day significantly increased first-phase insulin secretion by 118% versus placebo.
In plain wordsIn people with type 2 diabetes, liraglutide 1.25 mg raised early insulin release more than placebo.
Peptide
Liraglutide
Outcome
IncreaseFirst-phase insulin secretion
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.25 mg/day · 14 weeksAs given in this study (human).
Measurements
first-phase insulin secretion increase
118%
liraglutide 1.25 mg/day
Source sentences
Summary
The two highest doses of liraglutide (1.25 and 1.9 mg/day) significantly increased first-phase insulin secretion by 118 and 103%, respectively (P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the effect of liraglutide, a once-daily human glucagon-like peptide-1 analogue on pancreatic B-cell function. methods: Patients with Type 2 diabetes (n = 39) were randomized to treatment with 0.65, 1.25 or 1.9 mg/day liraglutide or placebo for 14 weeks.
Report a problemFND-1820121201
04HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, liraglutide 1.9 mg/day significantly increased first-phase insulin secretion by 103% versus placebo.
In plain wordsIn people with type 2 diabetes, liraglutide 1.9 mg raised early insulin release more than placebo.
Peptide
Liraglutide
Outcome
IncreaseFirst-phase insulin secretion
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.9 mg/day · 14 weeksAs given in this study (human).
Measurements
first-phase insulin secretion increase
103%
liraglutide 1.9 mg/day
Source sentences
Summary
The two highest doses of liraglutide (1.25 and 1.9 mg/day) significantly increased first-phase insulin secretion by 118 and 103%, respectively (P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the effect of liraglutide, a once-daily human glucagon-like peptide-1 analogue on pancreatic B-cell function. methods: Patients with Type 2 diabetes (n = 39) were randomized to treatment with 0.65, 1.25 or 1.9 mg/day liraglutide or placebo for 14 weeks.
Report a problemFND-1820121202
05HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, second-phase insulin secretion increased significantly with liraglutide 1.25 mg/day versus placebo.
In plain wordsIn people with type 2 diabetes, liraglutide 1.25 mg raised later insulin release more than placebo.
Peptide
Liraglutide
Outcome
IncreaseSecond-phase insulin secretion
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.25 mg/day · 14 weeksAs given in this study (human).
Source sentences
Summary
Second-phase insulin secretion was significantly increased only in the 1.25 mg/day group vs. placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the effect of liraglutide, a once-daily human glucagon-like peptide-1 analogue on pancreatic B-cell function. methods: Patients with Type 2 diabetes (n = 39) were randomized to treatment with 0.65, 1.25 or 1.9 mg/day liraglutide or placebo for 14 weeks.
Report a problemFND-1820121203
06HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, second-phase insulin secretion increased significantly only in the 1.25 mg/day group, not at 0.65 or 1.9 mg/day.
In plain wordsIn people with type 2 diabetes, the later insulin release rose only with the middle liraglutide dose.
Peptide
Liraglutide
Outcome
No significant changeSecond-phase insulin secretion
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.65 and 1.9 mg/day · 14 weeksAs given in this study (human).
Source sentences
Summary
Second-phase insulin secretion was significantly increased only in the 1.25 mg/day group vs. placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the effect of liraglutide, a once-daily human glucagon-like peptide-1 analogue on pancreatic B-cell function. methods: Patients with Type 2 diabetes (n = 39) were randomized to treatment with 0.65, 1.25 or 1.9 mg/day liraglutide or placebo for 14 weeks.
Report a problemFND-1820121204
07HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, arginine-stimulated insulin secretion increased by 114% with liraglutide 1.25 mg/day versus placebo.
In plain wordsIn people with type 2 diabetes, liraglutide 1.25 mg raised insulin release after an arginine challenge more than placebo.
Peptide
Liraglutide
Outcome
IncreaseArginine-stimulated insulin secretion
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.25 mg/day · 14 weeksAs given in this study (human).
Measurements
arginine-stimulated insulin secretion increase
114%
liraglutide 1.25 mg/day
Source sentences
Summary
Arginine-stimulated insulin secretion increased significantly at the two highest dose levels vs. placebo by 114 and 94%, respectively (P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the effect of liraglutide, a once-daily human glucagon-like peptide-1 analogue on pancreatic B-cell function. methods: Patients with Type 2 diabetes (n = 39) were randomized to treatment with 0.65, 1.25 or 1.9 mg/day liraglutide or placebo for 14 weeks.
Report a problemFND-1820121205
08HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, arginine-stimulated insulin secretion increased by 94% with liraglutide 1.9 mg/day versus placebo.
In plain wordsIn people with type 2 diabetes, liraglutide 1.9 mg raised insulin release after an arginine challenge more than placebo.
Peptide
Liraglutide
Outcome
IncreaseArginine-stimulated insulin secretion
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.9 mg/day · 14 weeksAs given in this study (human).
Measurements
arginine-stimulated insulin secretion increase
94%
liraglutide 1.9 mg/day
Source sentences
Summary
Arginine-stimulated insulin secretion increased significantly at the two highest dose levels vs. placebo by 114 and 94%, respectively (P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the effect of liraglutide, a once-daily human glucagon-like peptide-1 analogue on pancreatic B-cell function. methods: Patients with Type 2 diabetes (n = 39) were randomized to treatment with 0.65, 1.25 or 1.9 mg/day liraglutide or placebo for 14 weeks.
Report a problemFND-1820121206

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2NCT00154401

Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes

Novo Nordisk A/Sn = 177Jan 2005 to Oct 2005

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 25 Jan 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.